Keele Research Repository
Explore the Repository
Article
Wheatley, D, Haviland, J, Patel, J, Sydenham, M, Alhasso, A, Chan, C, Cleator, S, Coles, C, Donovan, E, Kirby, A, Kirwan, C, Nabi, Z, Sawyer, E, Somaiah, N, Syndikus, I, Venables, K, Yarnold, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 and Bliss, J (2022) First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. Radiotherapy and Oncology, 170. S75 - S76.
Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM and Yarnold, JR (2020) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, 152 (S1). S346 - S347.
Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, Chan, C, Churn, M, Cleator, S, Coles, CE, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, CC, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Bliss, JM, Yarnold, JR and FAST-Forward Trial Management Group, . (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395 (10237). 1613 - 1626.